Literature DB >> 21329049

Ibuprofen transdermal ethosomal gel: characterization and efficiency in animal models.

Margarita Shumilov1, Ronny Bercovich, Shaher Duchi, Denize Ainbinder, Elka Touitou.   

Abstract

A new ibuprofen transdermal nanosystem, designed by using an ethosomal carrier, was characterized and tested for its pharmacokinetic profile and therapeutic effects in animal models. It was found that the ethosomal nanosystem contains unilamellar vesicles with a normal size distribution of about 200 nm. The drug applied transdermally from the ethosomal gel was present in plasma for a longer period of time as compared to the oral administration and showed a high relative bioavailability. Ibuprofen plasma concentration reached a Cmax of 74.11 +/- 18.52 microg/ml 2 hours post application on rat skin. The ibuprofen ethosomal gel had an efficient antipyretic effect in fevered rats. Animal body temperature decreased to normal value gradually with duration of action of at least 12 hours compared to only 7 hours after the oral treatment. The transdermal ibuprofen gel also induced an analgesic effect 30 minutes following its application lasting for at least 6 hours. Biochemical and clinical hematological analysis results of the blood taken from animals in all experimental groups and those of skin histological examination show that ibuprofen ethosomal gel is safe and does not irritate the skin. Data obtained in this work suggest that the designed ethosomal ibuprofen gel could be further investigated in humans for its antipyretic effect.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21329049     DOI: 10.1166/jbn.2010.1153

Source DB:  PubMed          Journal:  J Biomed Nanotechnol        ISSN: 1550-7033            Impact factor:   4.099


  8 in total

1.  Scrolls: novel microparticulate systems for enhanced delivery to/across the skin.

Authors:  Irit Allon; Elka Touitou
Journal:  Drug Deliv Transl Res       Date:  2016-02       Impact factor: 4.617

2.  Herbal ethosomal gel containing luliconazole for productive relevance in the field of biomedicine.

Authors:  Vivek Dave; Nishant Bhardwaj; Nikita Gupta; Kajal Tak
Journal:  3 Biotech       Date:  2020-02-06       Impact factor: 2.406

Review 3.  Ethosomes as Nanocarriers for the Development of Skin Delivery Formulations.

Authors:  Ana Cláudia Paiva-Santos; Ana Luísa Silva; Catarina Guerra; Diana Peixoto; Miguel Pereira-Silva; Mahdi Zeinali; Filipa Mascarenhas-Melo; Ricardo Castro; Francisco Veiga
Journal:  Pharm Res       Date:  2021-05-25       Impact factor: 4.200

Review 4.  Ethosomal nanocarriers: the impact of constituents and formulation techniques on ethosomal properties, in vivo studies, and clinical trials.

Authors:  Ibrahim M Abdulbaqi; Yusrida Darwis; Nurzalina Abdul Karim Khan; Reem Abou Assi; Arshad A Khan
Journal:  Int J Nanomedicine       Date:  2016-05-25

Review 5.  Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties.

Authors:  Hiba Natsheh; Elka Touitou
Journal:  Molecules       Date:  2020-06-27       Impact factor: 4.411

Review 6.  Physical Enhancement? Nanocarrier? Current Progress in Transdermal Drug Delivery.

Authors:  Noriyuki Uchida; Masayoshi Yanagi; Hiroki Hamada
Journal:  Nanomaterials (Basel)       Date:  2021-01-28       Impact factor: 5.076

7.  Fabrication of Ethosomes Containing Tocopherol Acetate to Enhance Transdermal Permeation: In Vitro and Ex Vivo Characterizations.

Authors:  Naheed Akhtar; Naveed Akhtar; Farid Menaa; Walaa Alharbi; Fatima Saad Salem Alaryani; Ali Musfer Alqahtani; Faizan Ahmad
Journal:  Gels       Date:  2022-05-30

Review 8.  Topical Administration of Ibuprofen for Injured Athletes: Considerations, Formulations, and Comparison to Oral Delivery.

Authors:  Martin Anthony Christopher Manoukian; Christopher William Migdal; Amode Ravindra Tembhekar; Jerad Alexander Harris; Charles DeMesa
Journal:  Sports Med Open       Date:  2017-10-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.